#ASGCT26: Tessera reveals strongest data yet for in vivo sickle cell therapy

May 13, 2026 08:00 AM EDT R&DCell/Gene Tx Tessera says in­fu­sion ed­its 85% of blood cells, point­ing to off-the-shelf sick­le cell fix Ryan Cross Senior Science Correspondent BOSTON — Tessera Ther­a­peu­tics has cre­at­ed an ex­per­i­men­tal gene edit­ing drug for sick­le cell dis­ease that could com­pete with com­mer­cial cell ther­a­pies but is de­liv­ered … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER